ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats

Regeneron and Sanofi made a splash back in April with data from a first-line study in non-small cell lung cancer (NSCLC) showing that their PD-1 inhibitor Libtayo slashed the risk of death by 32% in patients with high levels of the biomarker PD-L1. Now, they're laying out more details from that study—data they hope will give Libtayo preferred status if it’s approved for previously untreated NSCLC patients.